To investigate which molecular pathways may be altered in rare, newly assigned DNA methylation-based diagnoses compared to WHO classifications, we compared their DNA methylation profiles with the largest subgroup in each cohort (IDH-mutant glioma in LTS, glioblastoma in STS). This evidence concerns the gene IDH1 and central nervous system cancer.